Session Details

F080 Cutaneous Lymphoma or Not? Clinicopathologic Challenges and Practical Pearls

Sun, Mar 10, 1:00 PM - 3:00 PM
Room 3
2 CME Available Forum
View Map

DESCRIPTION

This interactive session will present case-based diagnostic challenges including a wide range of cutaneous T- and B-cell lymphomas, from uncommon clinical variants of mycosis fungoides to rarer, more aggressive or life-threatening lymphomas. The goal is to familiarize audience members with clinical, histopathologic and molecular tools for diagnosis of cutaneous lymphomas, focusing on clues to distinguish lymphomas from inflammatory mimics. Implications for clinical management will also be discussed.

LEARNING OBJECTIVES

1.

Recognize uncommon presentations of mycosis fungoides and other cutaneous lymphomas based on clinical and histopathologic findings.

2.

Distinguish between cutaneous lymphoma and inflammatory mimics based on clinical and histopathologic findings, immunohistochemical studies, and molecular tests.

3.

Describe how accurately differentiating between cutaneous lymphomas and inflammatory mimics may impact the approach to clinical management.

SCHEDULE

1:00 PM

Welcome and introduction

Kerri Rieger, MD, PhD, FAAD

1:02 PM

Case presentations

Jennifer Yu Wang, MD, FAAD

1:22 PM

Case presentations

Erica Bo Kyung Wang, MD, FAAD

1:40 PM

Case presentations

Roberto Novoa, MD, FAAD

2:00 PM

Case presentations

Youn H. Kim, MD, FAAD

2:20 PM

Case presentations

Kerri Rieger, MD, PhD, FAAD

2:40 PM

Q&A and panel discussion

DIRECTOR

Kerri Rieger, MD, PhD, FAAD

Kerri Rieger, MD, PhD, FAAD

CO-DIRECTOR

Jennifer Yu Wang, MD, FAAD

Jennifer Yu Wang, MD, FAAD

SPEAKERS

Youn H. Kim, MD, FAAD

Youn H. Kim, MD, FAAD

Roberto Novoa, MD, FAAD

Roberto Novoa, MD, FAAD

Erica Bo Kyung Wang, MD, FAAD

Erica Bo Kyung Wang, MD, FAAD

DISCLOSURES

Youn H. Kim, MD, FAAD

Corvus Pharmaceuticals – Investigator(Grants/Research Funding); CRISPR Therapeutics – Investigator(Grants/Research Funding); Dren Bio, Inc – Investigator(Grants/Research Funding), Other(No Compensation Received); Innate Pharma S.A. – Other(No Compensation Received); Innate Pharma, S.A. – Investigator(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding), Speaker(Honoraria); Trillium Therapeutics, Inc – Investigator(Grants/Research Funding);

Roberto Novoa, MD, FAAD

Enspectra Health – Consultant(Stock Options); Iovance Biotherapeutics – Stockholder Public Company(Stock); L'Oreal USA Inc. – Investigator(Grants/Research Funding); Melanoma Research Alliance – Investigator(Grants/Research Funding); Moderna Therapeutics – Stockholder Public Company(Stock); Sanctum LLC – Advisory Board(Stock); Skin Analytics – Investigator(Grants/Research Funding);

Kerri Rieger, MD, PhD, FAAD

Kyowa Kirin – Advisory Board(Honoraria); Pfizer Inc. – Consultant(Fees);

Erica Bo Kyung Wang, MD, FAAD

No financial relationships exist with ineligible companies.

Jennifer Yu Wang, MD, FAAD

Enspectra Health – Consultant (1099 relationship)(Fees); Kyowa Kirin – Advisory Board(Honoraria);